DIAGNOS (OTCMKTS:DGNOF) (OTCMKTS:DGNOF) is a medical technology company focused on the development and commercialization of portable diagnostic imaging solutions. At the core of its business is a proprietary ultrasound platform built around capacitive micromachined ultrasonic transducers (CMUT) microchip arrays. This technology enables high-resolution imaging in a compact, handheld form factor, designed to bring advanced diagnostic capability out of the radiology suite and into point-of-care settings.
The company’s flagship product integrates advanced signal-processing software, cloud connectivity and optional AI-driven analytics modules, allowing clinicians to perform rapid assessments of cardiac, pulmonary and obstetric conditions. By combining real-time imaging with automated measurement tools, Diagnos aims to reduce exam times and improve diagnostic confidence, particularly in emergency departments, outpatient clinics and remote or resource-limited environments.
Originally spun out of the University of Toronto’s medical innovation ecosystem in the early 2010s, Diagnos has since expanded its footprint across North America and parts of Europe. The company collaborates with academic research centers and clinical partners to validate new applications, conduct multi-site trials and pursue regulatory clearances. Strategic distribution partnerships and service agreements help support equipment deployment, training and ongoing technical support for healthcare providers.
Diagnos is guided by a leadership team with deep experience in medical device R&D, regulatory affairs and healthcare commercialization. The executive group is supported by an advisory board of clinicians and imaging specialists, ensuring that product development remains aligned with real-world clinical needs. With a focus on innovation, quality and market access, Diagnos continues to advance its mission of making point-of-care ultrasound more accessible and effective around the world.
